Competition & Peer Data
API & CSV Delivery
Apollomics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Apollomics Inc (APLM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Peer Data As of Q4 2025
Competitors Tracked
-
Peer Group Market Share
100.00 %
Revenue Growth Y/Y
-
Net Margin
-128.69 %
Key Findings: Apollomics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 9M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Peer revenue share: Apollomics Inc accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
APLM Sales vs. its Competitors, Q4 2025
Apollomics Inc generated 100.00 % of the combined sales of its peer group.
APLM Stock Performance relative to its Competitors
APLM
Competitors (weighted)
Percent change over the selected range
Apollomics Inc's Comment on Competition and Industry Peers
The company operates in a highly competitive environment focused on the development and commercialization of new drugs, characterized by rapid technological advancements. Its clinical trials may face competition for patient enrollment from other trials targeting similar therapeutic areas, potentially causing delays and increased costs. Failure to secure regulatory approval for product candidates, including vebreltinib, could negatively impact the company's business. Competitors consist of major pharmaceutical firms, specialty pharmaceutical companies, biotechnology companies, universities, and other research institutions globally.